PFE Jun 2025 25.000 put
| Previous close | 1.5200 |
| Open | 1.8200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 25.00 |
| Expiry date | 2025-06-20 |
| Day's range | 1.6600 - 1.8200 |
| Contract range | N/A |
| Volume | |
| Open interest | 26.09k |
PR NewswireAstellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews. The volume of data being presented by Astellas reinforces its commitment to changing the cou
Simply Wall St.Pfizer Inc. Just Beat EPS By 61%: Here's What Analysts Think Will Happen Next
Pfizer Inc. ( NYSE:PFE ) just released its first-quarter report and things are looking bullish. It was overall a...
Barrons.comA Struggling Pfizer Looks for Help From a Wall Streeter
As the big drugmaker tries to turn its fortunes around by focusing on oncology, it has turned to a Citi analyst who hasn’t recommended the stock in over a decade. But Andrew Baum has something Pfizer needs: oncology expertise.
